Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

0.4251 -0.2528 (-37.29%)
Streaming Delayed Price Updated: 3:19 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medicus Pharma Ltd. - Common Stock

< Previous 1 2 3 Next >
News headline image
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Pipeline Presents Unique Opportunity To Capitalize On Rare Disease Market Worth Over $15 Billion
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
Topics Government World Trade
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Pipeline Presents Unique Opportunity To Capitalize On Rare Disease Market Worth Over $15 Billion
Via AB Newswire
Topics Government World Trade
Biotech’s Turning Point: 4 Stocks Poised to Ride the 2025 Wave (MDCX, ACTU, CRBU, NMRA)
Via AB Newswire
Topics Artificial Intelligence
Biotech’s Turning Point: 4 Stocks Poised to Ride the 2025 Wave
Via News Direct
Topics Artificial Intelligence
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market
Via AB Newswire
News headline image
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market 
Via News Direct
News headline image
Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market
Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market 
Via News Direct
Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market
Via AB Newswire
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Top movers in Friday's session ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Nasdaq Down 100 Points; Chicago PMI Dips In May ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Top movers in Friday's pre-market session ↗
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years 
From Quantum BioPharma
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-05-28: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio ↗
Medicus to acquire Antev and expand into urology with Teverelix while reporting positive data in its Phase 2 skin cancer trial for D-MNA. 
Via Benzinga
News headline image
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
This Millrose Properties Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.